Investment Rating - The report initiates coverage with a "Buy" rating for Jiangzhong Pharmaceutical, indicating a potential upside of 36% based on a target market value of 214 billion yuan compared to the current market value of 157 billion yuan [7][8]. Core Insights - Jiangzhong Pharmaceutical is positioned as a leader in gastrointestinal health, with a diversified business model encompassing OTC, prescription drugs, and health consumer products. The company has successfully built a strong brand presence with its well-known trademarks "Jiangzhong" and "Chuyuan" [5][16]. - The company has a robust product portfolio, including major products in the OTC market such as the 1 billion yuan "Jiangzhong Digestive Tablets" and the 500 million yuan "Lactobacillus Tablets" [7][36]. - The financial outlook is positive, with projected net profits for 2025-2027 expected to grow at compound annual growth rates of 8.3%, 10.0%, and 11.9%, respectively [6][8]. Summary by Sections Company Overview - Jiangzhong Pharmaceutical was established in 1969 and became publicly listed in 1998. The company has undergone significant restructuring and acquisitions, including the purchase of Jisheng Pharmaceutical and Sanghai Pharmaceutical, to enhance its market position [5][16]. - The company has a stable shareholding structure, with China Resources Group as the largest shareholder, which strengthens its operational capabilities and risk management [18][19]. Financial Data and Profit Forecast - The total revenue for 2024 is projected at 4.435 billion yuan, with a slight decline expected in 2025 before a recovery in subsequent years, reaching 5.089 billion yuan by 2027 [6]. - The gross profit margin is expected to remain stable around 65%, with the OTC segment showing a slight increase in profitability due to product mix optimization [26]. Investment Highlights - The company is focusing on expanding its OTC market presence by leveraging its strong brand and developing new product categories. The gastrointestinal product line is expected to maintain stable growth, while the health consumer products segment is anticipated to benefit from demographic trends such as aging populations [7][32]. - Jiangzhong Pharmaceutical's prescription drug segment is also expected to grow as the company continues to enhance its product offerings through acquisitions and strategic partnerships [7][32]. Market Position and Competitive Landscape - The company has maintained a leading market share in the OTC segment, particularly with its flagship product, the Jiangzhong Digestive Tablets, which ranked second in sales among digestive system medications in urban pharmacies [38][44]. - The competitive landscape for gastrointestinal products is fragmented, but Jiangzhong Pharmaceutical's brand strength allows it to maintain a dominant position [42][44].

行 业 及 产 业 轻工制造 行 业 研 究 / 行 业 点 评 证 券 研 究 报 告 证券分析师 庞盈盈 A0230522060003 pangyy@swsresearch.com 屠亦婷 A0230512080003 tuyt@swsresearch.com 黄莎 A0230522010002 huangsha@swsresearch.com 张海涛 A0230524080003 zhanght@swsresearch.com 张文静 A0230524120005 zhangwj@swsresearch.com 魏雨辰 A0230525010001 weiyc@swsresearch.com 联系人 魏雨辰 A0230525010001 weiyc@swsresearch.com 2025 年 12 月 23 日 扩内需提消费下关注个护、潮玩、 宠物等赛道；关注永艺股份报告 看好 —— 造纸轻工周报 2025/12/15-2025/12/19 本期投资提示： ⚫ 重点提示：1）内需消费：在扩大内需、提振消费的背景下，关注结构性消费机会，如国 货崛起的个护、相对高景气的宠物用品、悦己消费催化的 IP 潮玩 ...

Report Summary 1. Report Industry Investment Rating No industry investment rating information is provided in the report. 2. Report's Core View - The cycle sector of ETFs has rebounded, with the CSI Satellite Industry ETF leading in gains. The AI - themed new ETF issuance is hot, and the inflow of funds into the Huatai - Berry A500ETF is leading [1][23]. 3. Summary by Directory 3.1 Index Product Establishment, Raising, and Declaration - **Product Establishment and Listing**: In the recent week, 5 ETF products such as the Huatai - Berry CSI Science and Technology Innovation and Entrepreneurship Artificial Intelligence ETF were listed, and 13 products including the Huatai - Berry CSI Science and Technology Innovation and Entrepreneurship Artificial Intelligence ETF were established. The new issuance of AI - themed ETFs is hot, with products from Penghua, Morgan, and ICBC established [4]. - **Product Issuance Information**: In the coming week, 25 index products will end their fundraising, including the Southern Shanghai Science and Technology Innovation Board 50 Component ETF Linked A. And 8 index products will start fundraising, such as the ICBC Gemdale New Energy ETF on the Growth Enterprise Market and the Huaxia CSI All - Industry Food ETF [6]. - **Product Declaration Information**: In the recent week, 21 index products were declared. Among them, there are 9 theme funds such as the Taikang CSI Non - ferrous Metal Mining Theme ETF, and 5 cross - border - Hong Kong Stock Connect products like the Boshi Hang Seng Hong Kong Stock Connect High - Dividend Low - Volatility ETF [8]. 3.2 ETF Market Review - **Overall Market Performance**: In the recent week (2025/12/15 - 2025/12/19), most of the major broad - based A - share ETFs declined. The Science and Technology Innovation 50ETF and the Growth Enterprise Market 50ETF saw obvious pull - backs, with declines of - 2.92% and - 2.67% respectively. The major broad - based ETFs in Hong Kong and the US also pulled back synchronously. The Commodity ETFs showed different trends, with the Energy and Chemical ETF and the Gold ETF rising by 2.71% and 1.16% respectively [2]. - **Sector - Specific Performance**: Among the major industry ETFs, the cycle sector had the highest increase, with the Chemical ETF rising by 3.54%. Many sectors in the technology category faced pull - backs, such as the Chip ETF and the Electronic ETF, which declined by 3.03% and 3.02% respectively [15]. - **Cross - Border ETF Performance**: Among cross - border ETFs, the French CAC40 had the highest increase of 1.03%. The Huatai - Berry CSI KRX Korea - China Semiconductor ETF continued its previous volatile trend and declined by 4.80%. The Hong Kong - related ETFs all pulled back, with the Huatai - Berry Southern Dongying Hang Seng Technology ETF falling the most, by 2.84% [17]. 3.3 ETF Fund Flow - **Overall Scale and Change**: As of December 19, 2025, there were 1385 ETFs in the whole market, with a total scale of 5829.125 billion yuan, an increase of 52.135 billion yuan compared with the previous week. Among non - money ETFs, the ETFs targeting the CSI A500 had the largest net inflow of funds, reaching 32.702 billion yuan, while the ETFs targeting the CSI Short - Term Commercial Paper had the largest net outflow of 2.796 billion yuan [2][23]. - **Individual Product Performance**: In the recent week, the Huatai - Berry CSI A500ETF and the Harvest CSI AAA Science and Technology Innovation Corporate Bond ETF had relatively high fund inflows, with 8.688 billion yuan and 5.346 billion yuan respectively. The Haitong CSI Short - Term Commercial Paper ETF led in liquidity, with an average daily trading volume of 23.702 billion yuan in the recent week [28].

上 市 公 司 公 司 研 究 / 公 司 深 度 2025 年 12 月 23 日 中泰股份 (300435) ——稳健经营谋成长 深冷设备出海成为重要增长引擎 报告原因：强调原有的投资评级 买入（维持） | 市场数据： | 2025 年 12 月 22 日 | | --- | --- | | 收盘价（元） | 21.85 | | 一年内最高/最低（元） | 23.67/10.59 | | 市净率 | 2.5 | | 股息率%（分红/股价） | 0.92 | | 流通 A 股市值（百万元） | 8,059 | | 上证指数/深证成指 | 3,917.36/13,332.73 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 09 月 30 日 | | --- | --- | | 每股净资产（元） | 8.59 | | 资产负债率% | 26.85 | | 总股本/流通 A 股（百万） | 386/369 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： -50% 0% 50% 100% 12-23 01-23 02-23 03-23 0 ...

2025 年 12 月 23 日 周 期 板 块 迎 来 回 升 ， 华 泰 柏 瑞 A500ETF 净流入领先 ——指数化投资周报 20251222 ⚫ 产品成立募集情况： 产品成立方面，最近一周，汇添富恒指港股通 ETF、华泰柏瑞中证科创创业人工智能 ETF 等 5 只 ETF 产品上市；汇添富上证科创板 200 指数 A、人保中证 500 指数增强 A、东方 红中证全指指数增强 A 等 13 只产品成立。 募集方面，未来一周 25 只指数产品结束募集，8 只指数产品将开始募集。结束募集的指 数产品包括南方上证科创板 50 成份 ETF 联接 A 和国投瑞银创业板综合指数增强 A 等 25 只产品，开始募集的指数产品包括工银创业板新能源 ETF、华夏中证全指食品 ETF 等 8 只产品。 申报方面，最近一周共计 21 只指数产品进行申报，主题基金包括泰康中证有色金属矿业 主题 ETF、永赢中证畜牧养殖产业 ETF、鹏华中证电池主题 ETF 等 9 只产品；跨境-港股 通产品包括博时恒生港股通高股息低波动 ETF、广发标普港股通低波红利 ETF、工银瑞信 中证港股通医疗主题 ETF 等 5 只产品。 证 证 ...

郑菁华 A0230525060001 zhengjh@swsresearch.com 今日重点推荐 2025 年 12 月 23 日 人民币升值，"结汇潮"的助推——汇率双周报系列之六 10 月中旬以来，美元小幅贬值背景下、人民币大幅升值；这一非对称的涨 势引发了市场对"年终结汇"的热议。本轮升值是不是结汇推动、后续人 民币汇率的可能演绎？本文分析，供参考。 | 指数 | 收盘 | | 涨跌（％） | | | --- | --- | --- | --- | --- | | 名称 | （点） | 1 日 | 5 日 | 1 月 | | 上证指数 | 3917 | 0.69 | 2.15 | 1.28 | | 深证综指 | 2493 | 1.13 | 5.16 | 1.56 | | 风格指数 (％) | 昨日 | 近 1 个月 | 近 6 个月 | | --- | --- | --- | --- | | 大盘指数 | 0.86 | 3.48 | 20.31 | | 中盘指数 | 1.42 | 6.66 | 29.76 | | 小盘指数 | 1.12 | 5.06 | 25.03 | | 涨幅居前 行业(％) | ...

宏 观 研 究 "见微知著"系列报告 本研究报告仅通过邮件提供给 中庚基金 使用。1 2025 年 12 月 22 日 "返乡潮"提前了吗？ ——"见微知著"系列专题之九 ⚫ 一问：近期人流高位，是"返乡潮"吗？当前人流出行平稳高位，与返乡潮的脉冲上涨特征不同。 近期工业生产、基建投资有所回落下，跨区人流持续高位；部分观点认为"返乡潮"已提前到来。对 比过往，今年国庆假期后人流出行持续高位，全国迁徙指数同比维持在 15.3%较高水平。部分观点 指出当前人流出行走强可能源于近期工业生产、传统基建投资弱势表现，导致用工需求减少、促使务 工人员提前返乡；数据上招工信息搜索指数在 10 月下旬回落明显、当前已低于前两年同期水平。 从出行节奏看，当前人流更多呈现平稳高位运行态势，与返乡潮的脉冲式上涨特征不同。返乡期间， 劳务输出地的迁入指数、用工大省的迁出指数通常会同步出现"脉冲式"上行；譬如 2025 年春节前 6 天河南周口(劳务输入城市)的迁入指数、广东东莞(用工城市)的迁出指数分别冲高至 6.2、21.1，同 比分别上行至 50.6%、39.4%。而目前，两个地区的迁入、迁出指数走势均较为平稳。 从人流方向看， ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating for the sector [28]. Core Insights - The pharmaceutical sector has shown mixed performance, with the Shenwan Pharmaceutical and Biological Index down by 0.1% this week, while the Shanghai Composite Index increased by 0.03% [3][5]. - The overall valuation of the pharmaceutical sector stands at 29.2 times earnings, ranking 10th among 31 Shenwan primary industries [5][23]. Market Performance - The Shenwan Pharmaceutical and Biological Index ranked 22nd among 31 Shenwan primary sub-industries this week [3]. - The performance of various sub-sectors includes: - Raw materials (+0.5%) - Chemical preparations (-2.1%) - Traditional Chinese medicine (+0.2%) - Blood products (-0.3%) - Vaccines (-0.9%) - Other biological products (-0.7%) - Medical devices (+1.4%) - Medical consumables (+2.3%) - In vitro diagnostics (-0.8%) - Pharmaceutical distribution (+4.7%) - Offline pharmacies (+5.6%) - Medical research outsourcing (-0.9%) - Hospitals (+4.2%) [5][6]. Recent Key Events - Changchun High-tech signed an exclusive licensing agreement for GenSci098 with Yarrow, with potential milestone payments reaching up to $1.365 billion [10]. - Hansoh Pharmaceutical entered a multi-regional exclusive licensing agreement for Amivantamab with Glenmark, with potential payments exceeding $1 billion [12]. - Hengrui Medicine's subsidiary Kailera initiated three global Phase III clinical trials for HRS-9531, targeting obesity with and without diabetes [17]. - The FDA confirmed the legality of NMN as a dietary supplement, reversing a previous ban [15]. - The first invasive brain-machine interface for treating addiction-related mental disorders was approved in China [16]. Investment Opportunities - The report suggests focusing on domestic innovative drug companies due to the recovery of the CRO investment environment, highlighting companies such as Tigermed, Nossan, and others [2]. - As 2025 approaches its end, it is recommended to pay attention to valuation shifts in companies like WuXi AppTec, Hengrui Medicine, and others [2].

2025 年 12 月 22 日 对冲基金 Man Group 发行主动 ETF 海外创新产品周报 20251222 相关研究 证券分析师 沈思逸 A0230521070001 shensy@swsresearch.com 邓虎 A0230520070003 denqhu@swsresearch.com 联系人 沈思逸 A0230521070001 shensy@swsresearch.com 请务必仔细阅读正文之后的各项信息披露与声明 载 9T 美国 ETF 创新产品：Man Group 发行主动 ETF。上周美国共 35 只新发产品，新发数量 ● 维持高位。知名对冲基金 Man Group 上周发行 2 只主动 ETF，1 只为新兴市场选股产 品,主要采用基本面量化结合的方式选择长期有价值的股票并采用量化模型优化组合,产 品可同时选择多头、空头方向；另１只为趋势跟踪+股票产品，产品在 100%投资于美国 股票的同时，另有 100%的头寸投资于量化驱动的趋势跟踪策略，该策略通过国内外股 票、债券、商品期货等的趋势信号来执行方向性投资，希望获得与股票多头低相关的收益。 美国 ETF 资金流向：国内股票产品大幅 ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating an "Overweight" rating, suggesting that the industry is expected to outperform the overall market [30]. Core Insights - The report highlights recent developments in the pharmaceutical sector, including significant business development (BD) transactions involving companies like Changchun High-tech, Hansoh Pharmaceutical, and Hengrui Medicine, with potential milestone payments reaching billions of dollars [10][12][14]. - The approval of NMN as a dietary supplement in the U.S. and the submission of a new drug application for CagriSema, a GLP-1+Amylin combination therapy, are noted as key advancements in the industry [15]. - The report emphasizes the potential investment opportunities arising from the recovery of the domestic innovative drug environment, particularly in the CRO sector, with specific companies highlighted for consideration [2]. Market Performance - The report states that the Shenwan Pharmaceutical and Biological Index decreased by 0.1% this week, while the Shanghai Composite Index increased by 0.03% [3]. - Within the pharmaceutical sector, various sub-sectors showed mixed performance, with notable increases in medical supplies (+2.3%) and offline pharmacies (+5.6%), while chemical preparations (-2.1%) and blood products (-0.3%) declined [5][9]. Recent Key Events - Changchun High-tech signed an exclusive licensing agreement for GenSci098, with potential milestone payments of up to $1.365 billion [10]. - Hansoh Pharmaceutical entered into a multi-regional exclusive licensing agreement for Amivantamab, with potential payments exceeding $1 billion [12]. - The approval of a brain-machine interface for treating addiction marks a significant technological advancement in the industry [16]. Valuation Metrics - The overall valuation of the pharmaceutical sector is reported at 29.2 times earnings, ranking it 10th among 31 primary sectors [5][13]. - Specific companies within the sector have varying projected earnings per share (EPS) and price-to-earnings (PE) ratios, indicating diverse investment profiles [24].